Mydriasert (Phenylephrine Hydrochloride, Tropicamide)

Phenylephrine hydrochloride is an alpha‑1 adrenergic agonist. When applied to the eye, it stimulates alpha‑1 receptors on the iris dilator muscle, causing the muscle to contract and the pupil to enlarge. This effect complements the antimuscarinic action of tropicamide, resulting in a pronounced mydriatic response.

The specific dosing regimen for Mydriasert is determined by the prescribing eye care professional based on the indication, patient age, and clinical circumstances. The prescriber will decide the number of drops, concentration, and frequency required for safe and effective pupil dilation.

Safety data for Mydriasert in pregnancy and lactation are limited. The product should only be used if the potential benefit justifies any potential risk to the fetus or infant. Healthcare providers should evaluate each case individually and discuss possible risks with the patient.

To request Mydriasert, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mydriasert combines an alpha‑adrenergic agonist (phenylephrine) with an antimuscarinic (tropicamide), offering both rapid dilator action and cycloplegia. Compared with single‑agent drops such as atropine or phenylephrine alone, Mydriasert provides a balanced, predictable dilation with a shorter duration, which can be advantageous for same‑day procedures.

Mydriasert should be stored at room temperature, below 25 °C, in its original container. Protect the solution from direct light, moisture, and extreme temperature fluctuations. Keep the vial tightly sealed when not in use to maintain sterility.

Mydriasert is applied topically to the eye as a sterile ophthalmic solution. The prescriber typically instills one or more drops into the conjunctival sac of the target eye(s) using aseptic technique. The onset of dilation usually occurs within minutes, and the effect lasts for the period required for the procedure.

The most serious risks include acute angle‑closure glaucoma, severe allergic reactions such as anaphylaxis, and systemic cardiovascular effects like hypertension or tachycardia. Patients with narrow‑angle glaucoma or known hypersensitivity should be evaluated carefully before use.

Mydriasert is contraindicated in patients with known hypersensitivity to phenylephrine, tropicamide, or any component of the formulation. It should also be avoided in individuals with narrow‑angle or acute angle‑closure glaucoma, and in patients where excessive pupil dilation could compromise ocular health.